The workflow — which involves two immunoassays instead of the standard immunoassay followed by a Western blot — was tested using the agency's Lyme Serum Repository.

Although people have greater access to personalized drugs and tests than ever before, a survey by GenomeWeb and the PMC shows public awareness isn't improving.  

The study demonstrates that Veracyte's new test improves upon an earlier version in its ability to identify thyroid nodules that are likely to be benign.

The financing round will support Grail's ongoing development and validation of early cancer detection products.

The firm is positioning the technology, called Morffi, for use in lateral flow immunoassays, particularly in infectious disease diagnostics, such as influenza tests.

The findings run counter to historical data and may provide fodder to reconsider current guideline recommendations on surveillance of colorectal cancer patients.